Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune Response to Influenza Vaccine Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Strategies for Enhancing Mucosal Immunity to Influenza Vaccine

NCT01385215
View directory record Official record
Conditions
Mucosal Immunity
Interventions
Fluzone
Drug
Lead sponsor
John Sundy
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Beta-glucan and Immune Response to Influenza Vaccine

NCT05074303
View directory record Official record
Conditions
Healthy Aging
Interventions
Influenza Vaccine, Beta-glucan, Placebo
Biological · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 100 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

NCT01086566
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Jul 24, 2026, 4:39 AM EDT
Not listed Phase 4 Interventional

Optimizing Influenza Vaccination in Surgical Oncology Patients

NCT01698177
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

NCT06060457
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345, Fluzone HD
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
34
States / cities
Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of a Flu Vaccine in Children

NCT00001127
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (CAIV-T)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 18 Years
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 24, 2026, 4:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protective Immunity Project 02

NCT00833651
View directory record Official record
Conditions
Kidney Transplant, Immunology, Immunosuppression
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jul 24, 2026, 4:39 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.

NCT07386509
View directory record Official record
Conditions
Healthy
Interventions
Fluad® and Afluria® vaccination
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 49 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine

NCT00283283
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 64 Years
Enrollment
1,316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00347672
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

NCT00722774
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H2N2 1960 AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2008 · Synced Jul 24, 2026, 4:39 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

NCT02385123
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccine in Pediatric Transplant Subjects

NCT00133510
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Subviron Influenza vaccine (Fluzone)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccination in Bone Marrow Transplantation

NCT00419224
View directory record Official record
Conditions
Influenza
Interventions
inactivated split-virus influenza vaccine
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2007 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT05823974
View directory record Official record
Conditions
Influenza, Human
Interventions
F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z, F2B22C/DL001Z, F2B22D/DL001Z, F2B22E/DL001Z, F2F22A/DL001Z, F2F22B/DL001Z, F2F22C/DL001Z, F2F22D/DL001Z, F2F22E/DL001Z, Control 1, F2F23D/DL001Z-NH, F2F23A/DL001Z-NH, F2F23B/DL001Z-NH, Control 2, F2F23C/DL001Z-NH, Control 3, F2F22F/DL001Z
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
24
States / cities
Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

NCT01359150
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jul 24, 2026, 4:39 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

PET-CT Scans in Healthy Volunteers After Flu Vaccination

NCT00769002
View directory record Official record
Conditions
Flu
Interventions
FluShield, FluShield - same arm, FluShield - opposite arm, Blood Draws, FDG PET-CT Scan, Cytokine Profiling
Biological · Procedure · Genetic
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT06431607
View directory record Official record
Conditions
Influenza, Human
Interventions
F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH, F2H23H/DL001Z, FDQ23A-NH (Flu D-QIV), GSK5800544A, Flu D-TIV, F2H23A/DL001Z-NH, F2H23G/DL001Z, Fluzone HD Quadrivalent, Fluzone HD
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
845 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
18
States / cities
Hialeah, Florida • Miami, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Revealing Protective Immunity to Influenza Using Systems Immunology

NCT06501963
View directory record Official record
Conditions
Influenza
Interventions
Live Attenuated Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 24, 2026, 4:39 AM EDT
Completed No phase listed Observational

Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

NCT05584735
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Influenza vaccine, COVID-19 vaccine
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 1 Interventional

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

NCT05968989
View directory record Official record
Conditions
Influenza
Interventions
VRC-FLUMOS0116-00-VP( FLUMos-v2)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)

NCT00110279
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jul 24, 2026, 4:39 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Intradermal Influenza Vaccination

NCT06067555
View directory record Official record
Conditions
Vaccine Reaction
Interventions
MicronJet, Fluzone® Quadrivalent, Bacteriostatic Saline
Device · Biological · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jul 24, 2026, 4:39 AM EDT